Trial Profile
A retrospective, observational study evaluating the efficacy and safety of apatinib plus chemotherapy in patients with metastatic breast cancer in real world
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Jun 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2017 New trial record